Nanjing Vazyme Biotech Hits Day Low of CNY 17.80 Amid Price Pressure

Nanjing Vazyme Biotech Co., Ltd. experienced a notable decline today, with its stock price dropping by 5.03% to reach an intraday low of CNY 17.80. This performance stands in contrast to the China Shanghai Composite, which fell by 1.16% on the same day. Over the past week, Nanjing Vazyme has shown a positive trend, gaining 4.0%, but its one-year performance remains negative at -8.31%. The company has faced significant challenges, including a concerning annual decline in net sales of 22.47% and a staggering drop in operating profit of 154.52% over the last five years. Financial metrics indicate a low return on capital employed (ROCE) of 14.45%, reflecting limited profitability relative to total capital. Additionally, the company's debtors turnover ratio stands at a low 2.63 times, further highlighting operational inefficiencies. As a mid-cap player in the pharmaceuticals and biotechnology sector, Nanjing Vazyme's market capitalization is CNY 6,794 million, but it has consistently underperformed against the benchmark over the last three years, raising concerns about its long-term growth prospects.